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Alzheimer’s disease (AD) is the most common form of neurodegenerative disease that slowly 
impairs memory and thinking abilities. Abnormal accumulation and aggregation of amyloid  
peptides (A), derived from proteolytic cleavage of the amyloid precursor protein (APP), is 
thought to be one of the critical triggers in the pathogenesis. The trafficking and processing of 
APP is a complex process which can be regulated by many proteins. This thesis aims to 
expand our understanding of mechanisms that regulate processing and trafficking of APP.    
Study I aims to characterize the synaptic distribution of APP. We found that under normal 
conditions APP primarily distributed as fragments at synapses. Deletion of BACE1 led to an 
accumulation of APP C-terminal epitopes at synapses where APP N-terminal epitopes are 
present. A similar co-localization between APP N-terminals and C-terminals was also 
induced by pharmacological BACE1 inhibition. Moreover, proximity ligation assay revealed 
that the accumulation of APP C-terminals occurred in the presynaptic compartment. These 
results suggest that APP is primarily delivered to synapses as cleaved fragments, while full-
length APP can be transported to the presynaptic compartment under conditions of reduced 
BACE1 activity.  
Study II aims to evaluate mechanisms for how exercise and BDNF regulate α-cleavage of 
APP. It has been suggested that regular exercise can reduce A production. Moreover, 
exercise was suggested to enhance cognitive capacity, in which BDNF may contribute. We 
found that while the production of A was reduced, the levels of sAPP and BDNF were 
increased by exercise in a transgenic AD mouse model. Moreover, BDNF treatment was 
found to reduce A production by regulating -secretase activity. These results suggest that 
exercise and BDNF reduce Aβ production by enhancing -secretase processing of APP. 
Study III and IV involve two members from the protein family of sorting nexins (SNXs), 
which have diverse functions in protein sorting and trafficking.  
Study III aims to elucidate the role of SNX3 in APP trafficking and processing as well as in 
Aβ production. In this study, the expression of SNX3 was manipulated by overexpression. 
We found that overexpression of SNX3 reduced the formation of Aβ. Moreover, SNX3 
overexpression disturbed the association between APP and BACE1, and reduced APP 
internalization. While no change in BACE1 levels was found, APP levels were significantly 
decreased by SNX3 overexpression. These results suggest that overexpression of SNX3 
decreases A production by reducing internalization of APP.  
Study IV aims to test the involvement of SNX7 in Aβ production and APP processing. We 
found that overexpression of SNX7 decreased the levels of APP derived fragments, including 
Aβ. The cell surface and steady-state levels of APP, but not BACE1 were decreased by 
SNX7 overexpression. Moreover, the reduction of steady-state levels of APP was prevented 
by lysosomal inhibitors. Taken together, these results suggest that overexpression of SNX7 
reduces Aβ production by enhancing lysosomal degradation of APP. 
In summary, we have examined mechanisms that regulate APP trafficking and processing, 
which may help develop novel therapeutic strategies for AD.  
  
LIST OF SCIENTIFIC PAPERS 
 
I. Saket M. Nigam, Shaohua Xu, Frauke Ackermann, Joshua A. Gregory, 
Johan Lundkvist, Urban Lendahl, Lennart Brodin.  
Endogenous APP accumulates in synapses after BACE1 inhibition. Neurosci 
Res. 2016 Aug;109:9-15. 
 
II. Saket M. Nigam, Shaohua Xu, Joanna S. Kritikou, Krisztina Marosi, Lennart 
Brodin, Mark P. Mattson.  
Exercise and BDNF reduce Aβ production by enhancing α-secretase 
processing of APP. J Neurochem. 2017 Jul;142(2):286-296. 
 
III. Shaohua Xu, Saket M. Nigam, Lennart Brodin.  
Overexpression of SNX3 decreases amyloid-β peptide production by 
reducing internalization of amyloid precursor protein. Manuscript. 
 
IV. Shaohua Xu, Lu Zhang, Lennart Brodin.  
Overexpression of SNX7 reduces Aβ production by enhancing lysosomal 
degradation of APP. Biochem Biophys Res Commun. 2017 Nov 2. 
  
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Alzheimer’s disease (AD) ..................................................................................... 1 
1.2 Amyloid precursor protein (APP) ......................................................................... 3 
1.2.1 APP processing ......................................................................................... 4 
1.2.2 APP derived fragments ............................................................................. 5 
1.2.3 Subcellular trafficking of APP .................................................................. 6 
1.3 Secretases for APP ................................................................................................ 7 
1.3.1 -secretase ................................................................................................. 7 
1.3.2 -secretase ................................................................................................. 8 
1.3.3 -secretase ................................................................................................ 10 
1.3.4 Interplay of the α-, β-, and γ-secretase.................................................... 11 
1.4 Sorting nexins (SNXs) ........................................................................................ 12 
1.4.1 PX-only SNXs ......................................................................................... 14 
1.4.2 PX-BAR SNXs........................................................................................ 15 
1.4.3 PX-other SNXs ........................................................................................ 17 
1.4.4 SNXs in APP trafficking and processing ............................................... 20 
2 Aims ............................................................................................................................... 25 
3 Results and discussion ................................................................................................... 27 
3.1 Endogenous APP accumulates in synapses after BACE1 inhibition (Paper 
I) ........................................................................................................................... 27 
3.2 Exercise and BDNF reduce Aβ production by enhancing α-secretase 
processing of APP (Paper II) ............................................................................... 29 
3.3 Overexpression of SNX3 decreases amyloid-β peptide production by 
reducing internalization of amyloid precursor protein (Paper III) ..................... 30 
3.4 Overexpression of SNX7 reduces Aβ production by enhancing lysosomal 
degradation of APP (Paper IV) ........................................................................... 33 
4 Summary and future perspectives ................................................................................. 36 
5 Acknowledgements ....................................................................................................... 37 
6 References ..................................................................................................................... 39 
 
  
LIST OF ABBREVIATIONS 
AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
ADP Adenosine diphosphate 
AICD APP intracellular domain 
AP-2 Adaptor related protein complex 2 
APBA APP binding family A 
APLP APP‑like protein 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
ARF6 ADP ribosylation factor 6 
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BiFC Bimolecular fluorescence complementation 
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CTF C-terminal fragment 
ER Endoplasmic reticulum 
GGA Golgi-localized, γ-adaptin ear-containing, ADP ribosylation 
factor binding protein 
GTPase Guanosine triphosphate hydrolase 
HEK293T Human embryonic kidney cells 293T 
L1 L1 cell adhesion molecule 
LDLR Low density lipoprotein receptor 
LRP Low density lipoprotein receptor related protein 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NMDA N-Methyl-D-aspartate 
NRG1 Neuregulin 1 
PI3P Phosphatidylinositol 3-phosphate 
  
PI(3,4,5)P3 Phosphatidylinositol (3,4,5)-trisphosphate 
PI(3,5)P2 Phosphatidylinositol 3,5-bisphosphate 
PI(4,5)P2 Phosphatidylinositol 4,5-bisphosphate 
PLA Proximity ligation assay 
PX  Phox homology 
RA Retinoic acid 
SAP97 Synapse-associated protein 97; also known as discs large 
MAGUK scaffold protein 1 (DLG1) 
SH3  Src Homology 3 
SNX Sorting nexin 
SV2 Synaptic vesicle glycoprotein 2 
TGN Trans-Golgi network 
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1 INTRODUCTION 
1.1 ALZHEIMER’S DISEASE (AD) 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly that slowly 
impairs memory and thinking abilities. Since its first description in 1906 by Dr. Alois 
Alzheimer, many efforts have been placed on the investigation of underlying mechanisms 
and on the development of therapeutic approaches. However, the pathological mechanisms of 
AD remain incompletely understood and no treatment is so far available to cure the disease.  
AD is mainly featured by two pathological hallmarks: amyloid plaques and neurofibrillary 
tangles, as well as by synapse loss [1, 2]. Amyloid plaques are extracellular deposits largely 
composed of amyloid β peptides (Aβ), and neurofibrillary tangles are intracellular 
accumulations of abnormally phosphorylated tau protein. The relationships between the 
pathological features and the underlying mechanisms of AD have been controversial, and 
several hypotheses have been proposed, such as the amyloid cascade hypothesis, tau 
hypothesis, oxidative stress hypothesis and inflammation hypothesis [3]. Although no single 
hypothesis can fully explain the pathogenesis of AD, the amyloid cascade hypothesis is the 
most renowned proposal. 
In the amyloid cascade hypothesis, abnormal accumulation and aggregation of amyloid β 
peptides (Aβ) is thought to be a critical trigger in the pathogenesis of AD [4, 5]. Amyloid β 
(Aβ) is generated through sequential cleavage of the amyloid precursor protein (APP). 
Multiple Aβ peptides with different lengths have been described. The predominant peptide 
has 40 amino acids (Aβ40 or Aβ1-40), whereas Aβ42 is more prone to aggregate. Aβ can 
exist in several different assembly forms, of which three major groups are monomers, soluble 
oligomers, and insoluble fibrils [6]. The mechanism of Aβ aggregation is not fully 
understood, but it has been suggested that this process can be modulated by Aβ concentration, 
Aβ mutations and lengths, chemical modifications, lipid composition of membrane, and 
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cofactors such as the cholesterol carrier protein ApoE and metals [7, 8]. Soluble oligomers 
are believed to be the most toxic form, and they can induce numerous toxicities. For instance, 
it was found that Aβ oligomers can induce hyperphosphorylation of tau [9]. Tau is a 
microtubule associated protein which can stabilize the microtubule network. Abnormal 
hyperphosphorylation of tau promotes the protein to dissociate from the microtubules and to 
aggregate into neurofibrillary tangles [10]. Moreover, it has been suggested that Aβ 
oligomers can disrupt the function of a number of receptors, such as the NMDA receptor, the 
NGF receptor, and the cellular prion protein (PrPC), leading to synaptic dysfunction and 
neuronal death [11]. Synapses are specialized structures in neurons that propagate signals, 
and synapse loss correlates strongly with the cognitive decline in AD [12]. 
It is also important to note that Aβ, which is present at a low concentration in healthy 
individuals [13], is a physiological product. Aβ has been ascribed several physiological 
functions such as regulation of synaptic activity and involvement in memory formation [14, 
15]. In AD, because Aβ accumulates at a much higher level, it is prone to aggregate into 
deleterious oligomers.  
AD is a multifactorial brain disorder. It has been suggested that genetic, environmental, and 
life-style factors can contribute to the development of disease. Inherited familial AD has been 
mainly linked with three genes: APP, PSEN1 and PSEN2; and an additional copy of 
chromosome 21, where the APP gene resides, can cause AD type pathology. In addition, 
several genetic risk factors have been linked with AD, including ApoE ε4 [16]. Exercise, 
among other life-style factors, was found to reduce the risk of developing AD [17]. 
Moreover, it has been suggested that exercise can enhance cognitive capacity by increasing 
the mRNA and protein levels of BDNF (brain derived neurotrophic factor), a neurotrophic 
protein which is involved in the regulation of long-term potentiation and synaptic plasticity 
[18]. 
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1.2 AMYLOID PRECURSOR PROTEIN (APP) 
Amyloid precursor protein (APP), together with APP‑like proteins (APLPs) APLP1 and 
APLP2, belongs to an evolutionarily conserved protein family. These proteins have a similar 
domain structure, and share partially overlapping functions. They can also exhibit distinct 
functions: by analyzing different knockout mice (single knockout, double knockout, triple 
knockout), it has become clear that loss-of-function in one gene can not be fully compensated 
by others [19]. Notably, among them APP is the only one that can give rise to Aβ.  
APP is a type I transmembrane protein with multiple functional domains. It has a large 
extracellular region, in which several domains have been described to be implicated in 
functions such as dimerization and cell adhesion [20]. In the short cytoplasmic tail of APP, 
there is a YENPTY motif which contributes to the internalization of APP and also to 
interactions with adaptor proteins [2]. APP has multiple isoforms, the three major ones being 
APP695, APP751 and APP770. APP695 is the one that is predominantly expressed in neurons [2]. 
APP can undergo sequential cleavages to produce several different APP fragments (see 
section 1.2.1). 
In addition to the functions mediated by its fragments, APP, as a full-length protein, has been 
ascribed a number of functions. It was found that APP at the cell surface can form trans-
dimers with APP or its homologs to promote cell-cell adhesion [21], suggesting that full-
length APP may serve as a cell adhesion molecule. It has been proposed that APP may 
resemble a cell surface receptor [22, 23], and that the potential transsynaptic interaction 
between presynaptic and postsynaptic APP may promote synaptogenesis [24]. Moreover, 
fibrillar Aβ can bind to the cell surface APP [25], and the homodimerization of full-length 
APP can be induced by soluble Aβ [26], indicating that full-length APP may contribute to the 
signaling of Aβ toxicity. These findings suggest that APP can exhibit certain important 
functions as a full-length protein. However, its physiological functions largely remain 
unclear.   
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1.2.1 APP processing 
APP can undergo sequential cleavages in two routes: the non-amyloidogenic pathway and the 
amyloidogenic pathway [27, 28]. APP processing mainly involves three secretases: α-, β, and 
γ-secretase. As shown in Fig. 1, in the non-amyloidogenic pathway, APP is initially cleaved 
by α-secretase within the extracellular region to release a soluble N-terminal fragment, 
sAPPα; the remaining membrane-tethered C-terminal fragment, CTFα, can be further cleaved 
by γ-secretase to produce P3 peptides and an APP intracellular domain (AICD). 
Alternatively, in the amyloidogenic pathway, APP cleavage by β-secretase yields sAPPβ and 
CTFβ, the latter subsequently being cleaved by γ-secretase to generate Aβ and AICD.  
 
Fig. 1. Schematic diagram of APP processing. APP is a single-pass transmembrane protein with a 
large extracellular region and a short cytoplasmic tail. APP processing by α-, β-, and γ-secretase can 
occur in two routes to generate different APP derived fragments [27, 28]. The Aβ region is highlighted 
in red, and the secretase cleavage sites are shown along with the amino acid sequence of Aβ. 
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1.2.2 APP derived fragments 
sAPPα and sAPPβ 
sAPPα is generally thought to be beneficial to neurons [29]. It was found that sAPPα can 
facilitate neuritogenesis and LTP (long-term potentiation) [30]. Moreover, it has been shown 
that sAPPα can attenuate most of the deficits of APP knockout mice [31]. It may also be 
involved in cell proliferation [29, 30] and some other functions [32]. Recently it was found 
that sAPPα can inhibit β-cleavage of APP and Aβ production [33], suggesting that the 
neuroprotective functions of sAPPα may be partially dependent on pathways which are 
controlled by the APP β-cleaved fragments. sAPPβ is short of the C-terminal 16 amino acids 
in sAPPα. Similar to sAPPα it may also exhibit neuroprotective functions, but the effect is 
much less prominent [30] and may even be absent [29].  
CTFα and CTFβ 
Both CTFα and CTFβ are intermediate products during APP processing. CTFα can be 
derived by α-cleavage of APP as well as of CTFβ [34]. At present, the physiological function 
of CTFα is not clear. CTFβ was suggested to be neurotoxic [35]. In addition to being the 
precursor of Aβ, it has been implicated in endocytic dysfunction [36] and lysosomal 
pathology [37] independent of Aβ.  
P3 and AICD 
Possibly P3 can exhibit certain toxicity [38], but its physiological functions remain to be 
explored. AICD is considered to be involved in the regulation of transcriptional activity, in 
which the YENPTY motif and interactions with adaptor proteins may be essential [35, 39]. 
Importantly, it has been suggested that AICD targets genes including APP and BACE1 [39], 
suggesting that there may be a feedback mechanism for the regulation of APP processing. 
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1.2.3 Subcellular trafficking of APP 
APP trafficking is a complex process which is spatially and temporally regulated [28, 40-43]. 
After synthesis and initial modifications in the ER (endoplasmic reticulum), APP is 
transported to the Golgi apparatus and trans-Golgi network (TGN) where it undergoes full 
maturation involving multiple posttranslational modifications. A fraction of APP is delivered 
from the TGN to the plasma membrane where α-cleavage can take place. Non-cleaved APP 
is internalized via clathrin-mediated endocytosis to endosomes where β-cleavage 
predominantly occurs. From endosomes, remaining APP can be sorted into three routes [42]: 
retrograde transport to the TGN, recycling back to the cell surface, and delivery to lysosomes. 
The retrograde transport of APP can be regulated by many proteins, one significant factor of 
which is the retromer complex. The retromer is a multiprotein complex that regulates protein 
retrieval from endosomes to the TGN. Interestingly, it has also been implicated in protein 
recycling back to the cell surface [44]. It is believed that in mammals the retromer complex 
contains a cargo recognition subunit composed of VPS26, VPS29 and VPS35, and a SNX 
dimer subunit formed by different dimeric combinations of SNX1 or SNX2 with SNX5 or 
SNX6 [45]. In addition, at least two alternative retromer complexes may exist: SNX27-
retromer and SNX3-retromer [44, 46]. It has been found that these retromers are involved in 
retrograde trafficking of different cargos [46], and some of them have been implicated in APP 
trafficking [47, 48]. The recycling of APP back to the cell surface is not fully understood, and 
recently it was found that SNX15, in addition to SNX27 [47], may be involved in this process 
[49]. The degradation of APP occurs in lysosomes [50]. 
The trafficking of APP can be regulated by many other proteins, such as proteins in the Rab 
GTPase family, in the LDLR (low density lipoprotein receptor) family and in the 
APBA/MINT family [41, 43]. Importantly, several SNXs (sorting nexins) have been 
implicated in APP trafficking by different mechanisms (see section 1.4.4).  
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1.3 SECRETASES FOR APP 
1.3.1 -secretase 
It was proposed that in neurons the α-secretase cleavage of APP is constitutively executed by 
ADAM10 [51], a member of the ADAM (A disintegrin and metalloproteinase) family [52]. 
In addition, α-secretase cleavage of APP may be induced above the basal level by stimuli, 
which is referred to as regulated α-secretase cleavage [53]. Although not fully examined, 
several ADAMs have been implicated in regulated α-secretase cleavage. For instance, 
ADAM17 was found to contribute to the phorbol ester PMA stimulated APP α-cleavage [54]; 
and interestingly ADAM10 has also been involved in regulated APP α-cleavage by 
stimulation with the neuropeptide pituitary adenylate cyclase-activating polypeptide 
(PACAP) [55], and the drug acitretin [56]. The above findings indicate that ADAM10 plays a 
significant role in the α-secretase cleavage of APP. It has been suggested that regulated α-
secretase cleavage of APP primarily occurs in the TGN, while constitutive α-cleavage takes 
place at the cell surface [57-59]. 
Although little is known about the intracellular trafficking of ADAM10, several proteins have 
been found to be involved in α-cleavage of APP. For instance, SAP97 (synapse-associated 
protein 97) was found to regulate ADAM10 trafficking and α-secretase activity by a protein 
interaction through its SH3 (Src Homology 3) domain [60]. Moreover, it was revealed that 
the intracellular region of ADAM10 can interact with many SH3 domain-containing proteins, 
such as SNXs and PACSINs [61], suggesting that these proteins may also influence 
ADAM10-medicated cleavage. Indeed, for example, one of these proteins, SNX33, was 
found to promote α-cleavage of APP [62]. However, the functions of these proteins in 




With its β-secretase activity first reported in 1999 [63-66], BACE1 is now widely accepted as 
the principal β-secretase in the brain. BACE1 is a type I transmembrane aspartic protease 
with multiple domains including a cytosolic domain which contains an acidic cluster-
dileucine (ACDL) motif (DXXLL, where X denotes a nonconserved residue). 
After synthesis BACE1 is delivered to the plasma membrane. BACE1 can be internalized 
from the cell surface to early endosomes, and from endosomes it can undergo retrograde 
transport to the TGN, recycling to the cell surface, and delivery to lysosomes [67].   
It was found that internalization of BACE1 to early endosomes is controlled by the small 
GTPase ARF6 (ADP ribosylation factor 6) [68], which is clathrin-independent. Moreover, it 
has been proposed that BACE1 internalization can also occur through clathrin/AP-2-
dependent endocytosis [69, 70]. The ACDL in BACE1 (DISLL), which has been implicated 
in the internalization of BACE1 [71], appears to be mainly responsible for the association 
between BACE1 and the AP-2 complex [69]. In both the above cases, the dileucine motif was 
revealed to be essential in targeting BACE1 to early endosomes [68-70]. In addition, the 
ACDL motif was found to be involved in the interactions with the VHS domains in GGAs 
(Golgi-localized, γ-adaptin ear-containing, ADP ribosylation factor binding proteins) [72], 
which are a group of clathrin adaptors implicated in protein trafficking between endosomes 
and the TGN [73]. Therefore, it is not surprising that the retrograde transport of BACE1 can 
be regulated by GGAs [74, 75]. The associations between the dileucine motif and GGAs are 
enhanced by phosphorylation on the serine residue in ACDL (DISLL) [72, 76]. And it was 
suggested that phosphorylation on the ACDL motif can promote the retrograde transport of 
BACE1, whereas non-phosphorylated BACE1 is sorted to the plasma membrane [74]. 
Recycling of BACE1 back to the cell surface was recently found to be regulated by the 
GTPase Rab11 [77]. It is thought that the degradation of BACE1 can occur via the lysosomal 
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pathway [78] as well as the proteasomal pathway [79]. It is important to note that the 
trafficking of BACE1 involves many other proteins, including SNXs. It has been shown that 
SNX6, SNX12 and SNX4 can regulate BACE1 trafficking by different mechanisms (see 
section 1.4.4). 
The activity of β-secretase was found to be increased in the AD brain [80]. Given that 
BACE1 cleavage of APP is the initial and putatively rate-limiting step in Aβ production [81], 
it has been viewed as a prime drug target for AD therapy. However, besides APP, BACE1 
has numerous substrates [82], including CHL1 (neural cell adhesion molecule L1-like 
protein), NRG1 (neuregulin 1) and SCN2B (sodium channel subunit β-2), suggesting that it 
can display many different physiological functions by processing its substrates. Indeed, it has 
been revealed that BACE1(-/-) mice exhibit complex neurological defects, such as axon 
guidance defects, hypomyelination and seizures, in which different BACE1 substrates may be 
involved [83, 84].  
BACE1 activity has an acidic pH optimum, and it is primarily localized in acidic intracellular 
organelles, such as TGN and endosomes [84]. Endosomes are considered to be the site where 
β-cleavage of APP mainly takes place [77, 85]. Moreover, BACE1 cleavage of APP, but not 
NRG1 and L1 whose cleavage appears to be endocytosis-independent, was found to be 
selectively inhibited by an endosomally targeted β-secretase inhibitor [85]. Therefore, 
specifically targeting BACE1 activity in endosomes could be a promising therapeutic 
strategy. 
After the identification of BACE1, a homolog, BACE2 [86], was described. BACE2 has a 
low neuronal expression and preferred cleavage site within the Aβ sequence, making it 
unlikely to be a major β-secretase in the brain [83]. Instead, it was suggested to be involved in 
Down syndrome (DS) given that the gene is located on chromosome 21 and its expression is 
increased in DS patients [84]. 
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1.3.3 -secretase 
The γ-secretase is a multiprotein complex which is composed of presenilin (PSEN1 or 
PSEN2), nicastrin (NCT), anterior pharynx defective-1 (APH-1), and presenilin enhancer-2 
(PEN-2) [87]. The assembly, maturation and trafficking of γ-secretase is a very complex 
process [88, 89].  
γ-secretase has been shown to be a challenging drug target for AD therapy in that it has a 
wide range of substrates [90]. APP can be cleaved by γ-secretase at multiple sites to generate 
Aβ species with different C-terminals, ranging in length from 34 to 43 residues. Another 
significant substrate is the Notch protein, which has been implicated in numerous 
developmental and homeostatic processes [91]. Clinical trials have shown that γ-secretase 
inhibitors can cause significant side effects [92], possibly due to interference of cleavage of 
non-APP substrates, such as Notch. The activity of γ-secretase can be regulated by many 
proteins [93], one of them is the γ-secretase activating protein (GSAP) [94]. It was found that 
GSAP can influence Aβ production without affecting the cleavage of Notch [94]. These 
results indicate that γ-secretase may cleave its substrates by different mechanisms, suggesting 
that γ-cleavage of APP can be selectively modulated. Indeed, it was reported that some 
compounds can selectively inhibit the activity of γ-secretase in Aβ production while leaving 
the proteolysis of Notch intact [95]. Moreover, it was found that a class of compounds, 
referred to as the γ-secretase modulators, can shift Aβ production from Aβ42 to less 
pathogenic forms without changing the total amount of Aβ [93, 96]. It has been proposed that 
two strategies based on modification of the γ-secretase activity can be applied to develop 
treatments for AD [59]: 1) to develop γ-secretase inhibitors which are substrate-selective for 
APP; and 2) to develop efficient γ-secretase modulators. 
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1.3.4 Interplay of the α-, β-, and γ-secretase 
γ-cleavage occurs following α- or β- cleavage of APP. However, the activities of α-, β-, and 
γ-secretase are not absolutely separated. It was revealed that in neurons inhibition of BACE1 
is coupled with increased ADAM10 cleavage of APP [97]. ADAM10 was found to interact 
with γ-secretase [98]. Moreover, it has been shown that NCT and PSEN1 can bind to 
BACE1, and possibly regulate its maturation and activity [99-101]. But no interaction 
between ADAM10 and BACE1 was found [98]. These findings suggest that α- and β-
secretase can form different complexes with γ-secretase to regulate different sequential 
cleavages of APP.  
Therefore, it may be a good strategy to target the association between secretases while 
leaving the secretases activity unimpaired. Indeed, it has been reported that Aβ production 
and Aβ-related pathology can be reduced by blockade of the interaction between BACE1 and 
PSEN1 [102]. In addition, the association between APP and its secretases is an important 
prerequisite for APP cleavage, which may also serve as a target. Taken together, the 
associations between the secretases and secretase/substrate may represent a promising target 
for AD therapy.   
Although not discussed in this thesis, it is interesting to note that there may be additional 
secretases for APP processing, such as the η-secretase [103] and the δ-secretase (asparagine 
endopeptidase) [104] which have been described recently. 
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1.4 SORTING NEXINS (SNXS) 
Sorting nexins (SNXs) are a family of evolutionarily conserved proteins which are 
characterized by the presence of a PX (phox homology) domain. The PX domain was first 
described in p47phox and p40phox, two subunits of the NADPH oxidase (nicotinamide adenine 
dinucleotide phosphate-oxidase) complex [105]. It is now clear that the PX domain is also 
present in many other proteins, including members of the PLD (phospholipase D) 
superfamily, CISK (cytokine-independent survival kinase), and SNXs [106]. The PX domain, 
approximately 120 residues long, is a phosphoinositide-binding module [106]. It has been 
shown that the PX domain primarily interacts with PI3P, but can also bind to other 
phospholipids, such as PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P3 [107]. The different 
phosphoinositide-binding properties possibly allow targeting of PX domain-bearing proteins 
to distinct cellular membranes. Moreover, the PX domain has been implicated in interactions 
with other domains and proteins [108], suggesting that it may coordinate membrane 
recognition and protein complex assembly. Among the mammalian PX domain-bearing 
proteins, a group of homologous proteins are referred to as SNXs.  
The original family member of SNXs, SNX1, was identified in 1996 [109] and since then 
more than 30 putative human SNXs have been described. SNXs have been implicated in 
diverse functions, many of which relate to vesicular trafficking and protein sorting [110]. 
Based on structural similarities, SNXs can be divided into three subfamilies [111]: 1) PX-
only SNXs; 2) PX-BAR SNXs; and 3) PX-other SNXs (Fig. 2). 
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Fig. 2. Schematic diagram of the domain organization of putative human SNXs. Domain 
structures of 33 putative human SNXs. SNXs are divided into three subfamilies [111]: 1) PX-only 
SNXs (upper left); 2) PX-BAR SNXs (upper right); and 3) PX-other SNXs (lower group).   
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1.4.1 PX-only SNXs 
Proteins in this subfamily have only a PX domain without any other recognized domains. 
They are SNX3, SNX10, SNX11, SNX12, SNX16, SNX20, SNX21, SNX22 and SNX24. 
SNX10 and SNX11 
SNX10 was found to selectively interact with PI3P [112]. It can induce the formation of giant 
vacuoles in multiple mammalian cells, suggesting a fundamental role in the regulation of 
endosome homeostasis [113]. SNX11 can interact with PI3P and PI(3,5)P2 [114], and it has 
been implicated in protein trafficking from the plasma membrane to lysosomes [115].  
SNX16 
Although preferentially binding to PI3P [116], SNX16 was found to widely distribute in 
recycling endosomes, early endosomes, late endosomes and lysosomes [116, 117]. It has been 
shown that SNX16 is implicated in protein targeting to the lysosome [117] and recycling to 
the plasma membrane [118]. It is also involved in the regulation of late endosome dynamics 
[119] and synaptic growth signaling [120]. Moreover, SNX16 was proposed to be a negative 
regulator in cell migration and tumorigenesis [121].  
SNX20, SNX21, SNX22 and SNX24 
The phospholipid-binding property of SNX20 is elusive, in that some researchers showed its 
interactions with PI4P, PI5P and PI(3,5)P2 [122] whereas others indicated its bindings to 
PI3P and PI(4,5)P2 [123]. It was found that SNX20 can directly interact with the 
glycoprotein PSGL-1 and affect its subcellular localization [122]. The function of SNX21 is 
poorly studied, although its predominant expression in liver suggests an involvement in the 
development of this organ [124]. SNX22 was found to be involved in the CD4 
downregulation by HIV-1 in T cells [125], while SNX24 was shown to be a regulator of 
vascular inflammation [126]. 
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1.4.2 PX-BAR SNXs 
SNXs in this subfamily have, in addition to a PX domain, a C-terminal BAR domain, which 
can sense and induce membrane curvature [127, 128]. This subfamily includes SNX1, SNX2, 
SNX4, SNX5, SNX6, SNX7, SNX8, SNX9, SNX18, SNX30, SNX32, and SNX33. 
SNX1, SNX2, SNX5 and SNX6 
SNX1 was first identified in a yeast two-hybrid screen for the binding partners of EGFR 
[109]. It has an N-terminal Nexin_N domain which appears to be specific to SNX1 and 
SNX2. SNX1 and SNX2 share some redundant functions [129], but they can play distinct 
roles in protein trafficking [130]. SNX5 was found to interact with SNX1 [131], and SNX6 
can form heterodimers with SNX1 and SNX2 [132], suggesting that these proteins may 
coordinately regulate intracellular protein trafficking. SNX1, SNX2, SNX5 and SNX6 have a 
variety of functions, one of which is that they control protein transport by serving as subunits 
of the retromer complex [45].  
SNX8 
SNX8 was suggested to regulate retrograde protein transport [133], and cholesterol 
homeostasis [134]. Its C. elegans homolog was found to be a modifier of Aβ toxicity [135]. 
However, whether human SNX8 can exhibit similar effects, and if so by which mechanisms 
remain unknown.  
SNX9, SNX18 and SNX33 
Besides a PX and a BAR domain, these three SNXs have an additional N-terminal SH3 
domain, which is a protein interaction domain that can bind proline-rich ligands.  
SNX9 was found to have a variety of interaction proteins, including the AP-2 complex, 
clathrin and dynamin, and was suggested to play an important role in clathrin-mediated 
endocytosis [136-138]. SNX9 was also shown to be involved in the regulation of actin 
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assembly and membrane remodeling by its interactions with N-WASP and the Arp2/3 
complex [139]. Moreover, it has been implicated in cell invasion and cell division [140].  
Like SNX9, SNX18 can interact with dynamin and N-WASP [141], and was found to be 
involved in membrane remodeling [142]. In addition, SNX18 was shown to have an 
important role in the formation of autophagosomes [143]. SNX33 has been implicated in 
endocytosis and shedding of the cellular prion protein [144]. 
SNX9, SNX18 and SNX33 may share some redundant functions, as evidenced by that SNX9 
and SNX18 can compensate the loss-of-function of each other in clathrin-mediated 
endocytosis [141]. However, they also have irreplaceable functions, as supported by, for 
example, that all of them are essential for cell progression and completion of mitosis [145]. 
SNX30 and SNX32 
The functions of SNX30 and SNX32 are presently unclear.  
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1.4.3 PX-other SNXs 
The rest of the SNXs are grouped into the PX-other subfamily, and they contain different 
domains (other than BAR domains) in addition to a PX domain. This subfamily consists of 
12 members: SNX13, SNX14, SNX15, SNX17, SNX19, SNX23, SNX25, SNX26, SNX27, 
SNX28, SNX29 and SNX31.  
SNX13, SNX14, SNX19 and SNX25 
These SNXs have a PX domain, a PX associated domain (PXA) and a conserved C-terminal 
region (Nexin_C); an additional Regulator of G protein signaling (RGS) domain was 
identified in SNX13, SNX14 and SNX25. The functions of PXA and Nexin_C domains are 
unclear, and some RGS proteins have been implicated in G protein signaling by serving as 
GTPase activating proteins [146]. The domain organization of SNX13, SNX14 and SNX25 
suggests that they may provide a link between protein sorting and G protein signaling.  
The PX domain in SNX13 can bind to PI3P [147]. SNX13 can interact with the G protein 
subunit Gαs and regulate Gαs-mediated signaling [148], and it has been implicated in 
lysosomal protein degradation [148, 149]. In addition, SNX13 was found to play an essential 
role in embryonic development [150].  
The PX domain in SNX14 mainly associates with PI(3,5)P2 [151], but not with PI3P [147]. 
SNX14 was found to be localized in lysosomes, suggesting that it plays a role in the 
regulation of lysosomal function. Indeed, it was shown that mutations in SNX14 were 
associated with lysosomal dysfunction [151]. Moreover, SNX14 has been implicated in the 
regulation of normal neuronal excitability and synaptic transmission [152], and genetically 
linked with intellectual disability [151, 153]. 
SNX19 has broad phospholipid-binding properties [154] and it has been suggested to be 
involved in the regulation of lysosomal function and formation of membrane vesicles [155]. 
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Furthermore, it was found that SNX19 is implicated in the regulation of cell proliferation 
[156] and apoptosis [154]. 
SNX25 has been implicated in lysosomal degradation [157], and its expression was found to 
be increased in temporal lobe epilepsy [158]. Interestingly, SNX25 was suggested to be 
associated with age at onset in AD [159], but its functions remain largely unknown.  
SNX23 
SNX23 is also known as kinesin-like protein KIF16B. Transport of membranous vesicles and 
organelles along microtubules is driven by motor proteins, one type of which is the kinesin 
superfamily proteins (KIF). SNX23 is a member of the kinesin superfamily, and has been 
implicated in the relocation of early endosomes [160, 161], possibly by direct interaction 
between the PX domain and early endosome-enriched PI3P [162].  
SNX26 
SNX26 is also known as Rho GTPase-activating protein 33. Rho GTPase-activating (GAP) 
proteins can inactivate Rho GTPases by inducing GTP hydrolysis. SNX33 exhibits GAP 
activity in vitro [163], suggesting it may play a role in Rho GTPase signaling. SNX26 was 
found to be involved in the trafficking of the BDNF receptor TrkB [164]. Moreover, it can 
interact with PSD-95 [165], and has been implicated in neurite outgrowth [166] and synapse 
development [167]. 
SNX28 
SNX28 is also known as NADPH oxidase organizer 1 (NOXO1), which is a regulatory 
subunit of the NADPH oxidase complex. NADPH oxidase (NOX) is an important source of 
reactive oxygen species (ROS). Human NOX has seven members: NOX1, NOX2, NOX3, 
NOX4, NOX5, as well as two dual oxidases DUOX1 and DUOX2 [168]. Each member is 
different in their membrane-bound and cytosolic regulatory subunits, which are composed of 
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p22phox, p40phox, p47phox, p67phox, Rac, NOXA1, and NOXO1 [169]. It was found that 
NOXO1 can induce the activity of NOX1 [170] and NOX3 [171]. The PX domain in 
NOXO1 can interact with PI4P, PI5P and PI(3,5)P2, and is involved in the activation of 
NOX1 [172]. 
SNX29 
SNX29 is also known as RUN domain containing 2A (RUNDC2A). It has, in addition to a 
PX domain, an N-terminal RUN domain. Many RUN domain proteins have been proposed to 
be involved in Ras-like GTPase signaling and vesicle traffic [173, 174]. Although SNX29 has 
been associated with some diseases including schizophrenia [175], its function remains to be 
explored.  
SNX31 
SNX31, as well as SNX17 and SNX27, has a C-terminal 4.1/ezrin/radixin/moesin (FERM)-
like domain. A Ras GTPase-binding property has been attributed to the FERM-line domain, 
with which many proteins were proposed as adaptors in the endosomal trafficking and 
signaling [176, 177]. SNX31 preferentially binds to PI3P [178], and has been implicated in 
protein distribution at the cell surface [179]. 
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1.4.4 SNXs in APP trafficking and processing 
An association between SNXs and APP processing was first supported by the observation 
that SNX17 regulates APP turnover. Subsequently, several studies have linked other SNXs 
with different aspects of APP processing. 
SNX17 and SNX15  
SNX17 was identified as an intracellular adaptor for APP [180]. It has been found that 
SNX17 can interact with the NPXY motif of several proteins, including LDLR [181] and 
LRP [182]. Therefore, it is not surprising that SNX17 was found to directly bind to the 
YXNPXY motif of the APP cytoplasmic domain. Moreover, it was shown to colocalize with 
APP in early endosomes [180]. The gene expression of SNX17 was found to be decreased in 
an established APP transgenic mouse model [183], and it was revealed that SNX17, which 
can regulate Aβ production, influences APP turnover [180].  
SNX15 is widely expressed in rodent tissues [49]. It has been shown that SNX15 regulates 
the morphology of several endosomal compartments [184]. SNX15 can directly bind to 
clathrin [185], and it has been implicated in endocytosis of several proteins, including 
transferrin [184]. Unlike SNX17, SNX15 was shown to regulate Aβ generation by 
influencing APP recycling back to the cell surface [49]. 
SNX33 
SNX33, which primarily promotes α-cleavage, inhibits the endocytosis and increases the cell 
surface levels of APP [62]. These results suggest that SNX33 may facilitate APP α-cleavage 
by increasing the association between APP and α-secretase at the cell surface. SNX9, a 
homolog of SNX33, was shown to also increase α-cleavage of APP [62]. However, it is also 
important to note that SNX33 knockdown did not alter APP cleavage, possibly due to 
compensatory functions of the homologous SNX9 and SNX18, as proposed in the study. 
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Although SNX33 can influence APP endocytosis and shedding, it is unclear whether Aβ 
production is altered. 
SNX6, SNX12 and SNX4 
SNX6, which can reduce the production of sAPPβ and Aβ, was demonstrated to serve as a 
negative regulator of the retrograde transport of BACE1 [186]. SNX6 can directly interact 
with BACE1, and it has been suggested as a component of the multiprotein retromer complex 
[187]. Therefore, it is possible that SNX6 controls the retrograde transport of BACE1 by 
linking it to the retromer complex.  
Compared to SNX6, SNX12, which can also interact with BACE1, regulates Aβ production 
by a different mechanism in that SNX12 influences the endocytosis of BACE1 [188].  
SNX4 was shown to be a positive regulator of Aβ production by influencing BACE1 
degradation [189]. It can interact with BACE1, and direct BACE1 away from the lysosomal 
degradation pathway, thereby increasing the half-life and steady-state levels of BACE1. 
Moreover, SNX4 can also increase BACE1 levels at the plasma membrane. It has been 
previously reported that SNX4 can interact with clathrin [190] and is involved in endocytosis 
[191]. But it remains unclear whether the effect of SNX4 on BACE1 also involves the 
process of endocytosis. Interestingly, SNX4 protein levels were found to be reduced in brain 
samples of AD patients [189], which may reflect a rescue strategy to reduce Aβ production. 
However, the mechanisms that regulate SNX4 levels in AD remain unknown.  
The above results suggest that different SNXs may control different steps of BACE1 
intracellular trafficking.  
SNX27  
SNX27 is distinct from other SNXs in that it bears a unique PDZ (postsynaptic density 
95/discs large/zonus occludens 1) domain, which is a protein interaction module present in 
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many scaffold proteins [192]. SNX27 was suggested to be a subunit of the SNX27-retromer 
complex [193]. It has been mainly involved in endosome-to-cell surface protein trafficking 
[193, 194]. Moreover, SNX27 has recently been suggested to be implicated in endocytosis 
[195]. It has been shown that SNX27, which reduces Aβ production, influences the assembly 
and activity of γ-secretase complex by interaction with PSEN1 [196]. Furthermore, it was 
demonstrated to affect APP cleavage by regulating the endosome-to-cell surface recycling of 
APP [47]. These studies suggest that SNX27 can affect APP processing by multiple 
mechanisms.  
SNX3 and SNX7 
SNX3 is primarily localized in early endosomes. SNX3 can interact with VPS35 [197, 198], 
and clathrin [190], suggesting that it may be involved in several stages of endocytic 
trafficking. Indeed, SNX3 has been shown to be able to prevent protein delivery to lysosomes 
[199, 200], and to enhance protein transport to recycling endosomes [199] and the TGN 
[200]. It may also participate in endocytosis as it can regulate cell surface protein levels [197, 
199, 201]. SNX3 mRNA is expressed in several vulnerable brain regions in AD, such as the 
cerebral cortex and hippocampus [202]. Moreover, SNX3 was found to be enriched in the 
rodent postsynaptic density fraction [203], and it has been implicated in neurite outgrowth 
[204], a process that is compromised in AD [205]. In addition, it was found that single 
nucleotide polymorphisms (SNPs) in SNX3 are associated with AD [206]. 
SNX7 preferentially interacts with PI3P [199]. It was reported that SNX7 downregulation can 
induce the activation of caspase 8 [207], an alteration observed in AD brain [208]. Moreover, 
it has been shown that SNX7 is genetically associated with AD [209], and expression of the 
SNX7 gene was found to be decreased in AD subjects [210].  
It becomes clear that SNXs have emerged as key regulators in APP processing and 
trafficking. SNX3 and SNX7 have been linked with AD, but whether they can influence APP 
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processing and Aβ production remains unknown. In Study III and IV, we have examined the 
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2 AIMS 
The general aim of this thesis is to characterize the synaptic distribution of APP, and to 
investigate mechanisms that regulate APP trafficking and processing.  
Specific aims of the constituent papers are: 
1) to examine the fate of APP at synapses. 
2) to evaluate mechanisms for how exercise and BDNF regulate α-cleavage of APP. 
3) to elucidate the role of SNX3 in APP trafficking and processing as well as in Aβ 
production. 
4) to test the involvement of SNX7 in Aβ production and APP processing. 
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3 RESULTS AND DISCUSSION 
3.1 ENDOGENOUS APP ACCUMULATES IN SYNAPSES AFTER BACE1 
INHIBITION (PAPER I) 
Synapse loss is one of the key features in AD which correlates strongly with the cognitive 
decline in this disease [12]. Although the exact mechanism for the synaptic deficits is unclear, 
accumulating evidence indicates that Aβ derived from the proteolytic cleavage of APP plays 
a critical role [5]. APP has a number of functions in addition to giving rise to Aβ. It has been 
proposed that APP, as a full-length protein, is implicated in several synaptic functions, such 
as synaptogenesis [2, 24]. While the trafficking and processing of APP has been extensively 
studied in non-neuronal cells, the fate of APP in neurons and especially at synapses remains 
incompletely understood. The major β-secretase, BACE1, is an initial and putatively rate-
limiting enzyme in Aβ production. In study I, we combined immunocytochemistry and 
perturbation of BACE1 activity to examine the synaptic distribution of APP.  
Using antibodies directed to APP N-terminal epitopes (N-t1 and N-t2) and C-terminal 
epitopes (C-t1 and C-t2), we performed immunocytochemical characterization of APP on 
primary hippocampal neurons. In neurons derived from wild-type (BACE1(+/+) ) mice, APP 
N-terminal labeling predominantly overlapped with synaptic markers, whereas the APP C-
terminal labeling was largely separated from synapses, suggesting that APP primarily exists 
as fragments at synapses under normal conditions (Fig. 3). However, in neurons from 
BACE1(-/-) mice, while the N-terminal labeling remained similar to that in BACE1(+/+)  
neurons, C-terminal labeling showed a significant increase of co-localization with synaptic 
markers. These results suggest that more APP may distribute as a full-length protein at 
synapses when the activity of BACE1 is deficient. This idea was supported by the results that 
full-length APP levels were increased in the brains from BACE1(-/-) mice as compared to 
those from BACE1(+/+)  mice.  
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Fig. 3. Deletion of BACE1 
leads to co-accumulation of 
APP N-terminal and C-
terminal epitopes in synaptic 
regions [211]. (A, B) Double 
staining was performed with 
synaptotagmin (tag) or SV2 
antibodies and antibodies against 
the N-terminus of APP (N-t1, N-
t2, upper panels) and C-terminus 
of APP (C-t1, C-t2, lower 
panels) on primary hippocampal 
neurons from BACE1(+/+) mice 
(A) and in BACE1(−/−) mice (B). 
Scale bar = 2 μm. 
 
To confirm these results, we applied a pharmacological approach to inhibit BACE1 activity 
in rat hippocampal neurons. Similarly, APP N-terminal labeling showed a strong co-
localization with synaptic markers under both normal and the reduced BACE1 activity 
conditions. BACE1 inhibition led to a significant increase of the synaptic distribution of APP 
C-terminal epitopes, and thus more co-localization was found between the APP N-terminals 
and C-terminals after BACE1 inhibition. Taken together, these results indicate that full-length 
APP accumulates at synapses after inhibition of BACE1.   
To examine whether the above accumulation can occur in the presynaptic compartment, we 
took advantage of proximity ligation assay (PLA) which has a spatial resolution of about 40 
nm. Antibodies against the APP C-terminal and the synaptic vesicle marker SV2 were used 
for detection. A significant increase in PLA signals was found after BACE1 inhibition, 
suggesting that the above accumulation takes place in the presynaptic compartment [211].  
Our results indicate that at synapses APP mainly occurs as cleaved fragments, while a 
fraction of full-length APP can be transported to synapses, the latter process being enhanced 
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by reducing BACE1 activity. These results are in line with previous findings that APP 
secretases can be found in synaptic vesicles [212]. However, the role of the presynaptic 
compartment in APP processing remains to be elucidated.   
3.2 EXERCISE AND BDNF REDUCE AΒ PRODUCTION BY ENHANCING Α-
SECRETASE PROCESSING OF APP (PAPER II) 
It has been suggested that regular exercise, among other life-style factors, can reduce the risk 
of developing AD [17], and running wheel exercise can decrease Aβ production in AD 
transgenic models [18, 213]. Moreover, exercise has been suggested to enhance cognitive 
capacity by increasing the mRNA and protein levels of BDNF (brain derived neurotrophic 
factor) [18], a protein which has been implicated in APP processing and sAPPα production 
[214]. However, the exact mechanisms by which exercise can decrease Aβ production remain 
incompletely understood. In study II, we examined the relationship between exercise, BDNF 
and APP processing.   
Consistent with previous results showing that exercise can reduce Aβ levels in other AD mice 
models [213, 215], we found that runner mice showed a reduction of Aβ levels in hippocampi 
compared with sedentary control mice in a 2xTg AD (APP/PS1 double-mutant transgenic) 
mouse model. Moreover, the levels of both sAPPα and BDNF were increased in runner mice 
as compared to control mice.  
Previous studies indicate that BDNF can regulate sAPPα production [214]. To test whether 
BDNF may alter Aβ production by a mechanism involving α-cleavage of APP, we treated the 
differentiated SH-SY5Y cells with BDNF and/or the α-secretase inhibitor batimastat. 
Inhibition of the α-secretase activity led to an increase of both Aβ40 and Aβ42. BDNF 
treatment caused a significant reduction of Aβ levels. However, the effect of BDNF was 
occluded by batimastat, suggesting that the BDNF-induced reduction of Aβ levels was 
dependent on the α-cleavage.  
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Since ADAM10 has been suggested to be the constitutive α-secretase, we examined whether 
BDNF treatment can alter its levels and distribution. Protein levels of ADAM10 were 
revealed by Western blot, and no change was found. However, the cell surface levels of 
ADAM10 were significantly reduced upon BDNF treatment. These results together suggest 
that BDNF treatment may shift the distribution of ADAM10 from the cell surface to 
intracellular compartments where regulated α-secretase activity mainly takes place [216].   
Taken together, these results show that exercise can decrease Aβ production and increase 
sAPPα as well as BDNF levels, and suggest that BDNF plays an important role in the 
production of Aβ by regulating α-secretase activity. However, it is still unclear whether 
exercise regulates Aβ production through the pathways medicated by BDNF. In future 
studies, it will be of interest to examine whether exercise can still regulate Aβ generation 
when the function of BDNF is removed. 
3.3 OVEREXPRESSION OF SNX3 DECREASES AMYLOID-Β PEPTIDE 
PRODUCTION BY REDUCING INTERNALIZATION OF AMYLOID 
PRECURSOR PROTEIN (PAPER III) 
The trafficking and processing of APP is a complex process which can be regulated by many 
proteins. Among them sorting nexins (SNXs) have emerged as key players [41]. SNXs, 
characterized by a PX (phox homology) domain, is a family of evolutionarily conserved 
proteins [108, 111]. SNXs have diverse cellular functions many of which relate to protein 
trafficking and sorting [110]. SNX3, a member of the SNXs family, has a number of 
functions in protein sorting and trafficking [199, 200]. It was recently found that single 
nucleotide polymorphisms (SNPs) in SNX3 are associated with AD [206]. However, whether 
SNX3 directly affects APP processing and Aβ production remains unclear. In this study we 
provide a first test of this possibility. 
Overexpression of SNX3 together with APP in HEK293T cells significantly decreased the 
levels of both Aβ40, Aβ42 and sAPPβ as compared to empty vector control, whereas 
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overexpression of another SNX family protein, SNX29, did not lead to any alteration. 
Moreover, BACE1 levels were not altered by SNX3 overexpression. These results suggest 
that SNX3 can decrease amyloidogenic cleavage of APP.  
The association of APP with BACE1 is an important prerequisite for its β-cleavage. To test 
whether SNX3 can disrupt this association, we employed a bimolecular fluorescence 
complementation (BiFC) assay [217]. In this assay, APP is tagged with the non-fluorescent 
N-terminal fragment of the Venus protein (VN), while BACE1 is tagged with the non-
fluorescent C-terminal fragment of the Venus protein (VC) (Fig. 4). When APP and BACE1 
are in proximity, a functional 
Venus protein that produces a 
fluorescent signal is reconstituted. 
We found that overexpression of 
SNX3 resulted in a small but 
significant reduction in the 
association between APP and 
BACE1. These results suggest that 
SNX3 overexpression may 
decrease β-cleavage of APP by 
interference with the association 




Fig. 4. Principle of BiFC for the detection of 
association between APP and BACE1. APP and BACE1 
are C-terminally tagged with VN and VC fragment, 
respectively. Association between APP and BACE1 leads 
to formation of a functional Venus protein that produces a 
fluorescent signal. Adapted from Ref. [217]. 
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Since many lines of evidence indicate 
that APP encounters BACE1 in 
endosomes following its 
internalization [218, 219], we sought 
to test whether SNX3 affects the 
internalization of APP by using a 
well-established internalization assay 
[220]. APP was N-terminally tagged 
with an α-bungarotoxin-binding site 
(BBS). Internalization of APP was 
examined by monitoring cell surface 
BBS-APP labeled by incubation with 
α-bungarotoxin conjugated with 
Alexa Fluor® 555. We observed that 
overexpression of SNX3 decreased 
APP internalization (Fig. 5). 
Therefore, it would be expected that the cell surface distribution of APP would be enhanced 
by SNX3. Indeed, we found that the cell surface levels of APP, measured by flow cytometry, 
were significantly increased by SNX3 overexpression. These results together suggest that 
overexpression of SNX3 decreases Aβ production by reducing internalization of APP.  
These results coincide with previous findings suggesting that SNX3 may be involved in 
endocytosis of other cargo molecules [197, 201]. The precise role of SNX3 in endocytosis is 
unclear. However, it is interesting to note that that SNX3 can interact with the heavy chain of 
clathrin [200], suggesting that it may directly regulate the clathrin machinery. Our results 
suggest that SNX3 overexpression can affect Aβ production by influencing the association 
between APP and BACE1 as well as APP internalization. Therefore, modulation of SNX3 
Fig. 5. SNX3 overexpression inhibits APP 
internalization. HEK293T cells were co-transfected 
with empty vector (pEGFP-C1) or pEGFP-C1_SNX3 
and BBS-APP, and internalization of cell surface APP 
was examined. Scale bar = 10 µm. 
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may be an interesting approach to regulate amyloidogenic processing of APP while leaving 
the β-secretase activity unimpaired.   
3.4 OVEREXPRESSION OF SNX7 REDUCES AΒ PRODUCTION BY 
ENHANCING LYSOSOMAL DEGRADATION OF APP (PAPER IV) 
Many SNXs have been implicated in APP trafficking and processing. In this study, we 
extended the investigation to another protein, SNX7. SNX7 has, in addition to a PX domain, 
a C-terminal BAR domain, which can sense and induce membrane curvature [127, 128]. It 
was found that SNX7 downregulation can induce the activation of caspase 8 [207], an 
alteration observed in AD brain [208]. Moreover, it has been shown that SNX7 is genetically 
associated with AD [209], and expression of the SNX7 gene was found to be decreased in 
AD subjects [210]. However, it is still unclear whether SNX7 can influence APP processing 
and Aβ production. 
We found that overexpression of SNX7 in HEK293T cells decreased the levels of both Aβ40 
and Aβ42 as compared to empty vector control. Overexpression of another protein, SNX29, 
did not cause any change. Since β-secretase processing of APP is the putatively rate-limiting 
step in Aβ production [221], we next examined whether overexpression of SNX7 altered β-
cleavage. We found that SNX7 overexpression reduced the production of sAPPβ, suggesting 
that it may alter the β-cleavage of APP. The other β-cleavage product, CTFβ, was also 
examined. We found that SNX7 overexpression caused a significant decrease of both CTFβ 
and CTFα.  
It has been shown that SNX12 [222] and SNX4 [189] which influence processing of APP, 
can affect the cell surface levels of BACE1. To test whether SNX7 has a similar effect, we 
examined the cell surface distribution of BACE1 by confocal microscopy and flow 
cytometry. We found that SNX7 overexpression did not alter the cell surface levels of 
BACE1. In addition, no change of the steady-state levels of BACE1 could be detected by 
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overexpression of SNX7. These results suggest that overexpression of SNX7 does not 
influence Aβ production by affecting the cellular trafficking of BACE1. 
We then examined whether SNX7 can influence the trafficking of APP. As in the 
experiments above, the cell surface distribution of APP was examined by confocal 
microscopy and flow cytometry. We found that the cell surface levels of APP were decreased 
by SNX7 overexpression. Moreover, the steady-state levels of APP were also prominently 
reduced by overexpression of SNX7. These results suggest that SNX7 may alter Aβ 
production by influencing APP trafficking and processing.  
It has been shown that SNX4, which has a similar domain organization to SNX7, can 
influence protein trafficking to the lysosomal degradative pathway [189]. Therefore, it is 
possible that SNX7 overexpression affects APP levels by altering its degradation. To test this 
possibility, we used two compounds, NH4Cl [157, 223] and Bafilomycin A1 (Baf) [50, 189] 
to prevent protein degradation. As shown in Fig. 6, NH4Cl and Baf treatment both caused a 
significant increase of the APP levels, as expected by the known dependence of APP 
degradation on lysosomal pH [50, 224]. Consistent with the above results, SNX7 
overexpression reduced the APP levels. However, when NH4Cl or Baf was added, the effect 
of SNX7 overexpression was occluded, suggesting that the SNX7-induced reduction of APP 
was dependent on the degradative pathway [225]. 
This study has provided a first examination of the role of SNX7 in APP processing and Aβ 
production. We found that the levels of Aβ, sAPPβ, CTFs, cell surface APP and steady-state 
APP were decreased by SNX7 overexpression, which can all be explained by increased APP 
degradation. We do not, however, exclude the possibility that SNX7 additionally takes part in 
internalization of APP from the cell surface, a role linked with SNX33 [62] and SNX3 
(observations in Paper III). Taken together, these results suggest that overexpression of SNX7 
enhances APP degradation, thereby reducing Aβ production.  













Fig. 6. Lysosomal inhibitors prevent the reduction of APP levels by SNX7 overexpression [225]. 
A-D. HEK293T cells were co-transfected with either empty vector or FLAG-SNX7 together with 
Myc-APP. The cells were cultured for a total of 48 h after transfection. NH4Cl or Bafilomycin A1 
(Baf) was applied to the cultures 6 h before harvest. APP levels were examined by Western blot with 
anti-Myc antibody. Representative blots from NH4Cl treatment (A) and Baf treatment (C) experiments 
are shown. B. Quantification of APP levels in the NH4Cl treatment experiment. D. Quantification of 





4 SUMMARY AND FUTURE PERSPECTIVES 
The trafficking and processing of APP is a complex process which is spatially and temporally 
regulated. Interference with the trafﬁcking and subsequent localization of APP strongly 
inﬂuences APP processing, and thus Aβ production. This thesis aims to expand our 
understanding of mechanisms that regulate processing and trafficking of APP. We found that:  
1) APP mainly distributes as cleaved fragments at synapses under normal conditions. 
However, a pathway for the transport of full-length APP also exists, which can be revealed by 
reduction of BACE1 activity. 2) Exercise and BDNF can reduce Aβ production by enhancing 
α-cleavage of APP, and these effects were possibly regulated by ADAM10 distribution and 
activity. 3) Overexpression of SNX3 can disturb the association between APP and BACE1, 
as well as APP internalization, thereby reducing Aβ production. 4) SNX7 overexpression can 
decrease Aβ production by enhancing APP degradation. 
Considering that all the major secretases for APP have a number of substrates, it would 
possibly be very challenging to target them without any side-effects. In this thesis, we have 
shown that increased expression of SNX3 can decrease toxic Aβ production. Interestingly, 
while BACE1 levels were not altered, SNX3 can disturb the association between APP and 
BACE1, as well as APP internalization. The association between APP and BACE1 is an 
important prerequisite for β-cleavage and Aβ production. In principle specific targeting of the 
association would reduce Aβ production while leaving BACE1 activity intact. Therefore, the 
association between APP and BACE1 may be a promising therapeutic target. 
We provided a ﬁrst examination of the role of SNX3 and SNX7 in APP processing and Aβ 
production using HEK293T as a cell model. In future studies it will be of interest to examine 
whether these results apply also to other cell types, including primary neurons.  
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